Valuation: Abion Inc.

Market Cap 60.91B 45.56M 41.29M 38.19M 34.46M 64.94M 4.3B 67.23M 459M 182M 2.29B 171M 167M 7.28B P/E 2024
-4.02x
P/E 2025 -7.21x
Enterprise Value 32.57B 24.37M 22.08M 20.42M 18.43M 34.73M 2.3B 35.95M 245M 97.29M 1.23B 91.45M 89.51M 3.9B EV / Sales 2024
282x
EV / Sales 2025 288x
Free-Float
73.67%
Yield 2024 *
-
Yield 2025 -
07/04 ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs CI
04/04/25 Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc RE
30/12/24 Nuon Co., Ltd. completed the acquisition of 4.06% stake in ABION Inc. from KPM TECH Co., Ltd.. CI
26/12/24 KPM TECH Co., Ltd. announced that it has received KRW 5.999999711 billion in funding from ABION Inc. CI
23/12/24 Nuon Co., Ltd. agreed to acquire 4.06% stake in ABION Inc. from KPM TECH Co., Ltd. for KRW 8 billion. CI
23/12/24 ABION Inc. announced that it has received KRW 8.0011152 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
18/12/24 KPM TECH Co., Ltd. announced that it expects to receive KRW 5.999999711 billion in funding from ABION Inc. CI
05/12/24 ABION Inc. completed the acquisition of 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc.. CI
05/12/24 ABION Inc. announced that it has received KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
11/11/24 ABION Inc. announced that it expects to receive KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
11/11/24 ABION Inc. agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. for KRW 20.1 billion. CI
28/10/24 ABION Inc. announced that it expects to receive KRW 9.999995616 billion in funding from TELCON RF PHARMACEUTICAL. Inc. CI
28/12/23 Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc. CI
1 day-2.03%
3 months-2.03%
6 months-68.63%
Current year-78.40%
Current year 2,850
Extreme 2850
21,675
1 year 2,850
Extreme 2850
22,550
3 years 2,850
Extreme 2850
36,388.89
5 years 2,850
Extreme 2850
46,666.67
10 years 2,850
Extreme 2850
73,472.22
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2010
Director of Finance/CFO 45 28/03/2025
Chief Operating Officer 46 01/01/2026
Director TitleAgeSince
Director/Board Member 55 31/12/2014
Director/Board Member 56 25/03/2022
Director/Board Member 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
8/12/25 Free 27 0.0001% -
8/12/25 Buy 115 0.0002%
8/12/25 Free 92 0.0002% -
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%-.--%-73.83%-79.92% 45.56M
-2.69%-0.48%+51.67%+69.09% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
Average -0.76%-1.92%+26.60%+161.78% 41B
Weighted average by Cap. -0.83%+0.20%+37.22%+162.16%

Financials

2024 2025
Net sales 760M 568K 515K 476K 430K 810K 53.58M 838K 5.72M 2.27M 28.62M 2.13M 2.09M 90.86M 880M 658K 597K 552K 498K 938K 62.08M 971K 6.63M 2.63M 33.16M 2.47M 2.42M 105M
Net income -43.38B -32.45M -29.41M -27.2M -24.54M -46.25M -3.06B -47.88M -327M -130M -1.63B -122M -119M -5.19B -29.06B -21.74M -19.7M -18.22M -16.44M -30.99M -2.05B -32.08M -219M -86.8M -1.1B -81.59M -79.86M -3.48B
Net Debt 14.05B 10.51M 9.52M 8.81M 7.95M 14.98M 991M 15.5M 106M 41.95M 529M 39.43M 38.6M 1.68B -28.33B -21.2M -19.21M -17.77M -16.03M -30.21M -2B -31.27M -213M -84.62M -1.07B -79.54M -77.85M -3.39B
Projected Income Statement - Annual - Abion Inc.
Logo Abion Inc.
ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.
Employees
34
  1. Stock Market
  2. Stocks
  3. A203400 Stock